About this trial
The present study aimed to evaluate the impact of acute insomnia on long-term clinical outcomes in patients underwent PCI or CABG for AMI using the Korean National Health Insurance Service (NHIS) database, and to identify the factors through which insomnia contributes to prognostic determination in this patient population.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of acute myocardial infarction
Undergoing percutaneous coronary intervention or coronary artery bypass surgery
Disqualifiers
Pre-existing phychiatric disorders
Trial population
dults aged ≥18 years who were hospitalized between January 1, 2009, and December 31, 2023, with a primary diagnosis of AMI, defined using ICD-10 codes I21-I23 along with procedure codes for revascularization (either PCI or CABG), were included (N = 318,356). Among the participants, we excluded patients with mental disorder prior to incident MI (N =79,133), and patients who die at the diagnosis of AMI (N = 3,881).
Trial design
Cohort
Retrospective
Treatments tested in this trial
Insomnia medication
DrugDiagnosed as insomnia and use of anti-insomnia medication
No insomnia medication
Other interventionDiagnosed as insomnia and did not use of anti-insomnia medication
Treatment groups
Trial outcomes
Primary outcomes
Rates of MACCE
a composite of death, spontaneous MI, repeat revascularization, and ischemic stroke
Secondary outcomes
Rates of Death
All-cause death
Rates of Revascularization
repeat revascularization
Rates of Spontaneous MI
MI
Rates of Ischemic stroke
Stroke
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: